Senti Biosciences Holdings, Inc. (SNTI) · Nov 20, 2026 · Auditor change
Auditor change — KPMG dismissed; KNAV engaged
Senti Biosciences changed auditors with no reported accounting dispute, but the filing leaves its funding and going-concern pressure untouched.
Senti is now a much smaller, clinical-stage biotech focused on early Rett Syndrome and TIL programs after its October 2026 merger, while cash remains constrained and management says additional funding is needed to sustain operations beyond the second quarter of 2027. The auditor change does not alter that business situation. KPMG was dismissed and KNAV was engaged for fiscal 2026, but the filing reports no accounting disagreements or new reportable events; the only cited historical control issue was the material weakness that management said had already been remediated. 〔0〕
The main residual concern is context, not a new accounting problem. KPMG’s prior audit reports included a going-concern explanatory paragraph tied to recurring losses, negative operating cash flow, and the accumulated deficit. 〔1〕 That matters because Senti is already dependent on new capital, but this 8-K neither worsens nor resolves the funding problem. No clean expectation benchmark applies to an auditor transition; relative to the standing story, it is housekeeping rather than an operating or financing development.
Bottom line: The auditor switch is new disclosure but not a meaningful change to Senti’s underlying story. The company remains a cash-constrained biotech whose survival depends on additional funding, and this filing leaves that unchanged.
Additional financing or quarterly operating update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!